Integrating Genetics and Proteomes to Identify Novel Drug Targets for Alzheimer’s
Research News
|
Aug 23, 2021
Recently, Professor Yu Jintai, a researcher from the Neurology Department of Fudan University-affiliated Huashan Hospital and a Tianqiao and Chrissy Chen Institute (TCCI®) Investigator and his team identified seven genes including the angiotensin-converting enzyme (ACE) gene that can control the occurrence of Alzheimer’s disease at various transcriptomic and expression levels by integrating genetics and proteomes from brain and blood into their research strategy. Their findings are expected to help identify novel drug targets for Alzheimer’s disease. The research results have been published in Molecular Psychiatry (August 11, 2021; IF: 15.992) under the title “Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood”.
Other authors on this publication include Professor Zhang Can of Neurology at Harvard Medical School and Massachusetts General Hospital, professor Zhang Yanjiang of Department of Neurology in Daping Hospital, Third Military Medical University, professor Zhu Ying of Institutes of Brain Science, Fudan University, professor John Suckling of Department of Psychiatry of Cambridge University and professor Tan Lan of Qingdao Municipal Hospital.
Read the paper on the Molecular Psychiatry site
Recently, Professor Yu Jintai, a researcher from the Neurology Department of Fudan University-affiliated Huashan Hospital and a Tianqiao and Chrissy Chen Institute (TCCI®) Investigator and his team identified seven genes including the angiotensin-converting enzyme (ACE) gene that can control the occurrence of Alzheimer’s disease at various transcriptomic and expression levels by integrating genetics and proteomes from brain and blood into their research strategy. Their findings are expected to help identify novel drug targets for Alzheimer’s disease. The research results have been published in Molecular Psychiatry (August 11, 2021; IF: 15.992) under the title “Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood”.
Other authors on this publication include Professor Zhang Can of Neurology at Harvard Medical School and Massachusetts General Hospital, professor Zhang Yanjiang of Department of Neurology in Daping Hospital, Third Military Medical University, professor Zhu Ying of Institutes of Brain Science, Fudan University, professor John Suckling of Department of Psychiatry of Cambridge University and professor Tan Lan of Qingdao Municipal Hospital.
Read the paper on the Molecular Psychiatry site
